Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|September 27, 2024

Cost Drivers in Lupus Nephritis

Author(s)Ryan Haumschild, PharmD, MS, MBA, Jorge Larranaga, MD, Jeremy Wigginton, MD

Panelists discuss the main cost drivers of lupus nephritis treatment, comparing direct medical costs to those of other chronic conditions and examining indirect costs such as lost productivity and disability.

Episodes in this series

EP. 1 Understanding the Clinical Burden and Prevalence of Lupus Nephritis

EP. 1 Understanding the Clinical Burden and Prevalence of Lupus Nephritis

EP. 2 Cost Drivers in Lupus Nephritis

EP. 2 Cost Drivers in Lupus Nephritis

EP. 3 Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies

EP. 3 Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies

EP. 4 Guideline Updates in Lupus Nephritis: Impacts on Clinical Decision-Making

EP. 4 Guideline Updates in Lupus Nephritis: Impacts on Clinical Decision-Making

EP. 5 Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches

EP. 5 Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches

EP. 6 Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis

EP. 6 Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis

EP. 7 Improving Access to Lupus Nephritis Treatment: Strategies and Resources

EP. 7 Improving Access to Lupus Nephritis Treatment: Strategies and Resources

EP. 8 Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results

EP. 8 Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results

EP. 9 Collaborating for Better Care: Healthcare Providers and Payers in Lupus Nephritis

EP. 9 Collaborating for Better Care: Healthcare Providers and Payers in Lupus Nephritis

1 KOL is featured in this series.

EP. 10 From Guidelines to Practice: Advancing Lupus Nephritis Treatment

1 KOL is featured in this series.

EP. 11 Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice

What are the main cost drivers associated with the treatment and management of lupus nephritis?
How do direct medical costs for lupus nephritis compare with other chronic conditions?
What are some of the indirect costs (eg, lost productivity, disability) associated with lupus nephritis?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

ByNadege Gunn, MD

July 17th 2026

Navigating Treatment Sequencing and Defining Failure in Moderate-to-Severe Atopic Dermatitis

ByAngela J. Lamb, MD

July 17th 2026

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

ByNadege Gunn, MD

July 17th 2026

Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Unmet Needs and Emerging Mechanisms of Action in Extrapulmonary Neuroendocrine Carcinoma: The Path Toward Better Therapies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

Home-Based Heart Failure Care Shows Comparable Safety to Continued Inpatient Care

Voice Biomarkers Show Promise for Asthma, COPD Exacerbation Detection